Abstract 1454: MiR-517a mediates cisplatin sensitivity in bladder cell carcinoma

Abstract Cisplatin-containing neoadjuvant chemotherapy is the standard of care treatment for patients with muscle-invasive bladder cancer. We sought out to assess if miR-517a modulates sensitivity to cisplatin in bladder cancer cell lines. We used four transitional cell carcinoma cell lines T24, J82, UM-UC3 and TCCSUP. Cells were transfected with miR-517a mimic or inhibitor using lipofectaime according to manufacturer's instruction. Mtt assay was performed to assess viability after 96 hrs and clonogenic survival assays were performed to assess colony forming ability of cell lines. We found that miR-517a reduced proliferation and increased cisplatin sensitivity. Overexpression of miR-517a resulted in reduction of proliferation by 53%, 45%, 62% and 67% respectively (t-test p<0.05 for comparison with respective control cell lines). Transfection with miR-517a followed by cisplatin treatment resulted in a dramatic reduction in viability and colony forming ability of cells compared to cisplatin treatment alone. This reduction in viability was not observed after transfection with the miR-517a inhibitor. To our knowledge, this is the first report indicating that miR-517a functions as a sensitizer to cisplatin therapy in bladder cancer. Bioinformatics and microRNA target prediction databases identified several candidate genes. Note: This abstract was not presented at the meeting. Citation Format: Ahmed Ibrahim, Arnab Chakravarti, Tim Lautenschlaeger. MiR-517a mediates cisplatin sensitivity in bladder cell carcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1454. doi:10.1158/1538-7445.AM2014-1454